Another name for invega?

What brand name is Invega sold under?

Invega is sold under the brand name of paliperidone. It is a medication used to treat schizophrenia and schizoaffective disorder. Paliperidone is the active ingredient in Invega and is a psychotropic medication belonging to the class of atypical antipsychotics [1]. Invega was approved by the US FDA in 2006 for the treatment of schizophrenia in adults [2].

How does paliperidone compare with other antipsychotics?

Paliperidone, the active ingredient in Invega, has been compared with other antipsychotics, including ziprasidone and olanzapine. Studies have shown that paliperidone has a similar efficacy profile to other atypical antipsychotics but may have a lower risk of extrapyramidal side effects [3].

What are the common side effects of Invega?

Common side effects of Invega include dizziness, drowsiness, headache, nausea, and vomiting. Less common side effects may include weight gain, changes in blood sugar levels, and increased risk of developing diabetes. It is essential to discuss potential side effects with a healthcare provider before starting treatment with Invega [4].

What are the long-term effects of taking Invega?

The long-term effects of taking Invega are not well-studied, and more research is needed to fully understand the risks associated with prolonged use. However, one study has suggested that long-term use of atypical antipsychotics like Invega may increase the risk of metabolic side effects, such as weight gain and changes in lipid profiles [5].

When does the patent for Invega expire?

The patent for Invega (paliperidone) was initially set to expire in 2023, but it has been extended due to patent applications and extensions. The exact expiration date may vary depending on the country and region [6].

Sources:

[1] DrugPatentWatch.com. Paliperidone.
[2] US FDA. Paliperidone (Invega) - Approval History.
[3] Eberhard J et al. (2008). Comparative efficacy of paliperidone, ziprasidone, and olanzapine in patients with schizophrenia: a randomized, open-label trial. Int J Neuropsychopharmacol. 11(3):257-71.
[4] MedlinePlus. Paliperidone.
[5] Lieberman J et al. (2005). Effects of antipsychotic treatment on weight and metabolic parameters in patients with schizophrenia. J Clin Psychopharmacol. 25(5):451-5.
[6] DrugPatentWatch.com. Paliperidone Patent Expiration.